Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study
Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated. Patients treated at nine hospitals from December 2015 to...
Gespeichert in:
| Veröffentlicht in: | JGH open 2025-01, Vol.9 (1), p.e70081 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | e70081 |
| container_title | JGH open |
| container_volume | 9 |
| creator | Suga, Takayoshi Kakizaki, Satoru Naganuma, Atsushi Hatanaka, Takeshi Takakusagi, Satoshi Takizawa, Daichi Arai, Hirotaka Ueno, Takashi Iizuka, Keisuke Fukuchi, Toru Saito, Shuichi Tojima, Hiroki Yamazaki, Yuichi Uraoka, Toshio |
| description | Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated.
Patients treated at nine hospitals from December 2015 to December 2023 were included. Efficacy was assessed by comparing the proportion of patients achieving a platelet count ≥ 50 000/μL and the change in platelet count.
Seventy patients were eligible for evaluation. Patients with a pretreatment platelet count |
| doi_str_mv | 10.1002/jgh3.70081 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11686089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3150834746</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-dda22830b31b9b76195b41f85df2d0811988e08e9a132fe4c8cfc40a3ba171963</originalsourceid><addsrcrecordid>eNpVkctuFDEQRS0EIlHIhg9AXiKkDn70w2aDwjA8pEFEENaW212ecdTdnvgx0nwFv4ybhChsbJfq6twqX4ReUnJBCWFvb7Y7ftERIugTdMq47CpJOvL00fsEncd4QwihopMNb5-jk9KqGW3YKfq9Pugx6-T8jL3FaQd4ba0z2hyXepNjTsFPvd_rLbY-4NUu-NkZvHEHCPiji6Aj4A_lGHBhXAWorgPoNMGc8NWoE4yQ8MrnOcV3-BL_gMKLezCpAPC3PCZnirSwfqY8HF-gZ1aPEc7v7zP069P6evWl2nz__HV1uakMa0WqhkEzJjjpOe1l37VUNn1NrWgGy4byF1QKAUSA1JQzC7URxpqaaN5r2lHZ8jP0_o67z_0EwzJC0KPaBzfpcFReO_V_Z3Y7tfUHRWkrWiJkIby-JwR_myEmNbloYBz1DD5HxWlDBK-7ejF7cyc1ZfUYwD74UKKWFNWSovqbYhG_ejzZg_RfZvwPkEmasA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3150834746</pqid></control><display><type>article</type><title>Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study</title><source>Wiley-Blackwell Journals</source><source>Open Access: PubMed Central</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><creator>Suga, Takayoshi ; Kakizaki, Satoru ; Naganuma, Atsushi ; Hatanaka, Takeshi ; Takakusagi, Satoshi ; Takizawa, Daichi ; Arai, Hirotaka ; Ueno, Takashi ; Iizuka, Keisuke ; Fukuchi, Toru ; Saito, Shuichi ; Tojima, Hiroki ; Yamazaki, Yuichi ; Uraoka, Toshio</creator><creatorcontrib>Suga, Takayoshi ; Kakizaki, Satoru ; Naganuma, Atsushi ; Hatanaka, Takeshi ; Takakusagi, Satoshi ; Takizawa, Daichi ; Arai, Hirotaka ; Ueno, Takashi ; Iizuka, Keisuke ; Fukuchi, Toru ; Saito, Shuichi ; Tojima, Hiroki ; Yamazaki, Yuichi ; Uraoka, Toshio</creatorcontrib><description>Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated.
Patients treated at nine hospitals from December 2015 to December 2023 were included. Efficacy was assessed by comparing the proportion of patients achieving a platelet count ≥ 50 000/μL and the change in platelet count.
Seventy patients were eligible for evaluation. Patients with a pretreatment platelet count < 40 000/μL had a significantly lower rate of achieving a platelet count of ≥ 50 000/μL than those with a pretreatment count of 40 000-50 000/μL (62.5% vs. 84.2%,
= 0.038); however, there was no significant difference in the change in platelet count (25 700 vs. 24 400/μL,
= 0.972). Patients with viral-related cirrhosis showed a significantly greater change in platelet count than the others (29 100 vs. 19 200/μL,
= 0.012). For patients receiving multiple lusutrombopag treatments, the change in platelet count was significantly lower in the second treatment than in the first treatment (26 900 vs. 20 800/μL,
= 0.041). The main adverse event observed was thrombosis (2.9%).
Lusutrombopag increases platelet count regardless of pretreatment levels, but efficacy, defined as achieving a platelet count of ≥ 50 000/μL, may be insufficient in patients with a pretreatment platelet count < 40 000/μL. Additionally, patients with non-viral liver disease responded less well to treatment compared to those with viral liver disease. Therefore, treatment strategies should be tailored based on pretreatment platelet counts and the etiology of liver disease.</description><identifier>ISSN: 2397-9070</identifier><identifier>EISSN: 2397-9070</identifier><identifier>DOI: 10.1002/jgh3.70081</identifier><identifier>PMID: 39742152</identifier><language>eng</language><publisher>Australia: Wiley Publishing Asia Pty Ltd</publisher><subject>Original</subject><ispartof>JGH open, 2025-01, Vol.9 (1), p.e70081</ispartof><rights>2024 The Author(s). JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><rights>2024 The Author(s). published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c268t-dda22830b31b9b76195b41f85df2d0811988e08e9a132fe4c8cfc40a3ba171963</cites><orcidid>0000-0003-3656-285X ; 0009-0003-0711-5791 ; 0000-0001-8417-1461 ; 0000-0002-2004-8285 ; 0000-0003-0224-7093 ; 0000-0003-0663-0102 ; 0000-0002-4425-4331</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686089/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686089/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39742152$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suga, Takayoshi</creatorcontrib><creatorcontrib>Kakizaki, Satoru</creatorcontrib><creatorcontrib>Naganuma, Atsushi</creatorcontrib><creatorcontrib>Hatanaka, Takeshi</creatorcontrib><creatorcontrib>Takakusagi, Satoshi</creatorcontrib><creatorcontrib>Takizawa, Daichi</creatorcontrib><creatorcontrib>Arai, Hirotaka</creatorcontrib><creatorcontrib>Ueno, Takashi</creatorcontrib><creatorcontrib>Iizuka, Keisuke</creatorcontrib><creatorcontrib>Fukuchi, Toru</creatorcontrib><creatorcontrib>Saito, Shuichi</creatorcontrib><creatorcontrib>Tojima, Hiroki</creatorcontrib><creatorcontrib>Yamazaki, Yuichi</creatorcontrib><creatorcontrib>Uraoka, Toshio</creatorcontrib><title>Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study</title><title>JGH open</title><addtitle>JGH Open</addtitle><description>Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated.
Patients treated at nine hospitals from December 2015 to December 2023 were included. Efficacy was assessed by comparing the proportion of patients achieving a platelet count ≥ 50 000/μL and the change in platelet count.
Seventy patients were eligible for evaluation. Patients with a pretreatment platelet count < 40 000/μL had a significantly lower rate of achieving a platelet count of ≥ 50 000/μL than those with a pretreatment count of 40 000-50 000/μL (62.5% vs. 84.2%,
= 0.038); however, there was no significant difference in the change in platelet count (25 700 vs. 24 400/μL,
= 0.972). Patients with viral-related cirrhosis showed a significantly greater change in platelet count than the others (29 100 vs. 19 200/μL,
= 0.012). For patients receiving multiple lusutrombopag treatments, the change in platelet count was significantly lower in the second treatment than in the first treatment (26 900 vs. 20 800/μL,
= 0.041). The main adverse event observed was thrombosis (2.9%).
Lusutrombopag increases platelet count regardless of pretreatment levels, but efficacy, defined as achieving a platelet count of ≥ 50 000/μL, may be insufficient in patients with a pretreatment platelet count < 40 000/μL. Additionally, patients with non-viral liver disease responded less well to treatment compared to those with viral liver disease. Therefore, treatment strategies should be tailored based on pretreatment platelet counts and the etiology of liver disease.</description><subject>Original</subject><issn>2397-9070</issn><issn>2397-9070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNpVkctuFDEQRS0EIlHIhg9AXiKkDn70w2aDwjA8pEFEENaW212ecdTdnvgx0nwFv4ybhChsbJfq6twqX4ReUnJBCWFvb7Y7ftERIugTdMq47CpJOvL00fsEncd4QwihopMNb5-jk9KqGW3YKfq9Pugx6-T8jL3FaQd4ba0z2hyXepNjTsFPvd_rLbY-4NUu-NkZvHEHCPiji6Aj4A_lGHBhXAWorgPoNMGc8NWoE4yQ8MrnOcV3-BL_gMKLezCpAPC3PCZnirSwfqY8HF-gZ1aPEc7v7zP069P6evWl2nz__HV1uakMa0WqhkEzJjjpOe1l37VUNn1NrWgGy4byF1QKAUSA1JQzC7URxpqaaN5r2lHZ8jP0_o67z_0EwzJC0KPaBzfpcFReO_V_Z3Y7tfUHRWkrWiJkIby-JwR_myEmNbloYBz1DD5HxWlDBK-7ejF7cyc1ZfUYwD74UKKWFNWSovqbYhG_ejzZg_RfZvwPkEmasA</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Suga, Takayoshi</creator><creator>Kakizaki, Satoru</creator><creator>Naganuma, Atsushi</creator><creator>Hatanaka, Takeshi</creator><creator>Takakusagi, Satoshi</creator><creator>Takizawa, Daichi</creator><creator>Arai, Hirotaka</creator><creator>Ueno, Takashi</creator><creator>Iizuka, Keisuke</creator><creator>Fukuchi, Toru</creator><creator>Saito, Shuichi</creator><creator>Tojima, Hiroki</creator><creator>Yamazaki, Yuichi</creator><creator>Uraoka, Toshio</creator><general>Wiley Publishing Asia Pty Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3656-285X</orcidid><orcidid>https://orcid.org/0009-0003-0711-5791</orcidid><orcidid>https://orcid.org/0000-0001-8417-1461</orcidid><orcidid>https://orcid.org/0000-0002-2004-8285</orcidid><orcidid>https://orcid.org/0000-0003-0224-7093</orcidid><orcidid>https://orcid.org/0000-0003-0663-0102</orcidid><orcidid>https://orcid.org/0000-0002-4425-4331</orcidid></search><sort><creationdate>20250101</creationdate><title>Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study</title><author>Suga, Takayoshi ; Kakizaki, Satoru ; Naganuma, Atsushi ; Hatanaka, Takeshi ; Takakusagi, Satoshi ; Takizawa, Daichi ; Arai, Hirotaka ; Ueno, Takashi ; Iizuka, Keisuke ; Fukuchi, Toru ; Saito, Shuichi ; Tojima, Hiroki ; Yamazaki, Yuichi ; Uraoka, Toshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-dda22830b31b9b76195b41f85df2d0811988e08e9a132fe4c8cfc40a3ba171963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suga, Takayoshi</creatorcontrib><creatorcontrib>Kakizaki, Satoru</creatorcontrib><creatorcontrib>Naganuma, Atsushi</creatorcontrib><creatorcontrib>Hatanaka, Takeshi</creatorcontrib><creatorcontrib>Takakusagi, Satoshi</creatorcontrib><creatorcontrib>Takizawa, Daichi</creatorcontrib><creatorcontrib>Arai, Hirotaka</creatorcontrib><creatorcontrib>Ueno, Takashi</creatorcontrib><creatorcontrib>Iizuka, Keisuke</creatorcontrib><creatorcontrib>Fukuchi, Toru</creatorcontrib><creatorcontrib>Saito, Shuichi</creatorcontrib><creatorcontrib>Tojima, Hiroki</creatorcontrib><creatorcontrib>Yamazaki, Yuichi</creatorcontrib><creatorcontrib>Uraoka, Toshio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JGH open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suga, Takayoshi</au><au>Kakizaki, Satoru</au><au>Naganuma, Atsushi</au><au>Hatanaka, Takeshi</au><au>Takakusagi, Satoshi</au><au>Takizawa, Daichi</au><au>Arai, Hirotaka</au><au>Ueno, Takashi</au><au>Iizuka, Keisuke</au><au>Fukuchi, Toru</au><au>Saito, Shuichi</au><au>Tojima, Hiroki</au><au>Yamazaki, Yuichi</au><au>Uraoka, Toshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study</atitle><jtitle>JGH open</jtitle><addtitle>JGH Open</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>9</volume><issue>1</issue><spage>e70081</spage><pages>e70081-</pages><issn>2397-9070</issn><eissn>2397-9070</eissn><abstract>Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated.
Patients treated at nine hospitals from December 2015 to December 2023 were included. Efficacy was assessed by comparing the proportion of patients achieving a platelet count ≥ 50 000/μL and the change in platelet count.
Seventy patients were eligible for evaluation. Patients with a pretreatment platelet count < 40 000/μL had a significantly lower rate of achieving a platelet count of ≥ 50 000/μL than those with a pretreatment count of 40 000-50 000/μL (62.5% vs. 84.2%,
= 0.038); however, there was no significant difference in the change in platelet count (25 700 vs. 24 400/μL,
= 0.972). Patients with viral-related cirrhosis showed a significantly greater change in platelet count than the others (29 100 vs. 19 200/μL,
= 0.012). For patients receiving multiple lusutrombopag treatments, the change in platelet count was significantly lower in the second treatment than in the first treatment (26 900 vs. 20 800/μL,
= 0.041). The main adverse event observed was thrombosis (2.9%).
Lusutrombopag increases platelet count regardless of pretreatment levels, but efficacy, defined as achieving a platelet count of ≥ 50 000/μL, may be insufficient in patients with a pretreatment platelet count < 40 000/μL. Additionally, patients with non-viral liver disease responded less well to treatment compared to those with viral liver disease. Therefore, treatment strategies should be tailored based on pretreatment platelet counts and the etiology of liver disease.</abstract><cop>Australia</cop><pub>Wiley Publishing Asia Pty Ltd</pub><pmid>39742152</pmid><doi>10.1002/jgh3.70081</doi><orcidid>https://orcid.org/0000-0003-3656-285X</orcidid><orcidid>https://orcid.org/0009-0003-0711-5791</orcidid><orcidid>https://orcid.org/0000-0001-8417-1461</orcidid><orcidid>https://orcid.org/0000-0002-2004-8285</orcidid><orcidid>https://orcid.org/0000-0003-0224-7093</orcidid><orcidid>https://orcid.org/0000-0003-0663-0102</orcidid><orcidid>https://orcid.org/0000-0002-4425-4331</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2397-9070 |
| ispartof | JGH open, 2025-01, Vol.9 (1), p.e70081 |
| issn | 2397-9070 2397-9070 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11686089 |
| source | Wiley-Blackwell Journals; Open Access: PubMed Central; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals |
| subjects | Original |
| title | Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A31%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20Efficacy%20of%20Lusutrombopag%20for%20Chronic%20Liver%20Disease%20Based%20on%20Pre-Treatment%20Platelet%20Counts:%20A%20Retrospective%20Multicenter%20Study&rft.jtitle=JGH%20open&rft.au=Suga,%20Takayoshi&rft.date=2025-01-01&rft.volume=9&rft.issue=1&rft.spage=e70081&rft.pages=e70081-&rft.issn=2397-9070&rft.eissn=2397-9070&rft_id=info:doi/10.1002/jgh3.70081&rft_dat=%3Cproquest_pubme%3E3150834746%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3150834746&rft_id=info:pmid/39742152&rfr_iscdi=true |